Phase II Trial of ISIS 2503, an Antisense Inhibitor of H-Ras, in Patients With Advanced Pancreatic Cancer.
Phase of Trial: Phase II
Latest Information Update: 27 Jan 2016
At a glance
- Drugs ISIS 2503 (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 03 Feb 2010 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 17 Dec 2009 Actual patient number (4) added as reported by ClinicalTrials.gov.
- 19 Sep 2005 New trial record.